Eğer anlattığın gibiyse, gayet mantıklı, kendileri açısından. Deva ya giren çıkan bir şey olmaz. Bizim devleti böyle söğüşlemek lazım zaten(dolayısıyla olan ülkeye oluyor). Adam gibi ilaç zamları yapılsa bu işlere hiç gerek kalmaz.
Printable View
https://www.accessdata.fda.gov/scrip...l_No=210197#44
https://www.ilacabak.com/desefin-1-g...-1-flakon-1873
2024 yılının ilk FDA onayı ülkemizde DESEFIN(4 farklı form için) ismindeki ilacımız için gelmiş. Bununla birlikte 17 ruhsatımız oldu. Hayırlı uğurlu olsun ortaklara..
pdf dosya indirim :Alıntı:
Royalty Rates The vast majority of the deals involve the payment of running royalties as a percent of net sales
once commercialization of the licensed technology is achieved. Running royalties are required in 412 of the deals studied - 92.6% of the total 445 deals in this book. Not all of the deals requiring the payment of running royalties disclosed the actual royalty rate to be paid but royalty rates were disclosed for 345 deals. Royalty rates are either negotiated as a fixed percentage rate for all sales or a range of percentages rates as sales achieve designated levels. As such, many deals specified a range of royalty rates that can be characterized as the high-end royalty rate and the low-end royalty rate. For all of the deals that reported royalty rates, the average of the high-end royalty rate was 9.7%.
The average low-end royalty rate was 6.9%. The highest royalty rate in the data base was 50% of net sales for a recombinant form of the human enzyme. One of the lowest rates was 0.25% of net sales associated with a monoclonal antibody for cancer therapy. Summarized below is the royalty rate data discovered in the license agreements.
It is easy to see that the vast majority of royaty rates are at the lower end of scale. In fact, over 50% of the deals involve royalty rates of 6% of sales or less. Over 76% of the deals involve royalty rates of 10% or less. Over 90% of the deals involve royalty rates of 20% or less. Put another way, only 10% of all the deals studied involved royalty rates of 20% or more. Royalty payments based on a portion of profits were extremely rare.
https://techtransfercentral.com/wp-c...mple-Pages.pdf
selec eski zirvesine yüzde 10 kaldı bizim yüzde 25. ne özelliği var anlamıyoruz dağıtıcı nasıl uçar gider. almadan satıyor sanırım bundan dolayı. üreten sürünüyor ecilc ve deva.
hedef büyük olunca çer çöp toplayacaksın
son üç haftada citi alımı 400.000 lota yaklaştı
ve de hisseyi baskılayarak
fonlardan ucuz almak için tam bir kumpanya var
küçücük lotlar bile önemli
çünkü yol uzun
yat.fon işlemlerinin incelenmesi gerekiyor her tahtada